With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.105627-79-0,Isoquinoline-5-sulfonyl chloride hydrochloride,as a common compound, the synthetic route is as follows.
To a solution of the amine (27 mg, 0.0792 mmol) in DCM (1 ml) at 0 C was added triethylamine (55 mu1, 0.396 mmol). Isoquinoline-5-sulphonyl chloride hydrochloride (21 mg, 0.0792 mmol) was added in one portion and the resulting solution warmed to rt and stirred for 20 h. The reaction mixture was then concentrated, dissolved in MEOH (1 ml) and 1 M HC1 in diethyl ether (2 ml) added. After stirring for 3.5 h, the mixture was concentrated and purified by SCX-2 Isolute column (washing with MEOH, then 1 M NH3 in MEOH) to give the desired product as an oil (31 mg, 53% over 3 STEPS). 1H NMR (CDCL3) 8 1.44-1. 52 (1H, m), 1.92-2. 06 (1H, m), 2.67-2. 75 (2H, m), 2.88-3. 05 (2H, m), 3.45-3. 52 (1H, m), 3.98-4. 03 (1H, m), 4.37 (2H, s), 7. 13-7. 35 (4H, m), 7.67-7. 74 (1H, m), 8.17-8. 23 (1H, m), 8.43-8. 46 (2H, m), 8.69- 8.73 (1H, m), 9.37 (1H, d). LC/MS : Rt 4.87 [M+H] 432.
As the paragraph descriping shows that 105627-79-0 is playing an increasingly important role.
Reference£º
Patent; ASTEX TECHNOLOGY LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED; THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL; WO2005/11697; (2005); A2;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem